Montreal Heart Institute

Rémi Marcoux named “Founder Emeritus” of TC Transcontinental

Retrieved on: 
Tuesday, January 23, 2024

MONTRÉAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Transcontinental Inc. (TSX: TCL.A TCL.B) announced today that Rémi Marcoux, founder of TC Transcontinental and member of the Board, has not sought re-election as a director.

Key Points: 
  • MONTRÉAL, Jan. 23, 2024 (GLOBE NEWSWIRE) -- Transcontinental Inc. (TSX: TCL.A TCL.B) announced today that Rémi Marcoux, founder of TC Transcontinental and member of the Board, has not sought re-election as a director.
  • Mr. Marcoux's term will end on March 13, at the annual shareholders’ meeting.
  • In recognition of his entrepreneurial career and his significant contribution to the vision, growth and development of the Company in keeping with its values, the Board has named Mr. Marcoux “Founder Emeritus”.
  • Rémi Marcoux, founder of TC Transcontinental, said: “I built this great company, which I founded in 1976, with a long-term vision and a desire for continuity, and my wishes have come true.

Ceapro Inc. Announces Dosing of First Patients in Phase 1-2a Study Assessing Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Retrieved on: 
Wednesday, December 13, 2023

EDMONTON, Alberta, Dec. 13, 2023 (GLOBE NEWSWIRE) --  Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced the commencement of patient dosing in its Phase 1-2a study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation. No adverse reactions have been observed and the study can be pursued as per protocol design.

Key Points: 
  • “The start of patient dosing in the Phase 1-2a study is a significant accomplishment and step forward in providing a promising new therapeutic in low grade systemic inflammation,” stated Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro .
  • “We are pleased with this rapid dosing stage of the study being led by Dr. Tardif and his team.
  • Following the Phase 1 portion, pending successful results, the AvenActive protocol also includes a Phase 2a portion for patients presenting evidence of mild to moderate inflammation.
  • The Phase 1-2a trial is designed to evaluate the safety profile of avenanthramides and gather initial insights into its potential efficacy.

Ceapro Inc. Initiates Phase 1-2a Study Assessing Its Flagship Product Avenanthramides for Potential Applications in Inflammation Based Diseases

Retrieved on: 
Monday, November 27, 2023

EDMONTON, Alberta, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc.  (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients and disruptive technologies for healthcare and cosmetic industries, announced today the initiation of its Phase 1 study evaluating its flagship product, avenanthramides, for potential applications in managing conditions related to inflammation.

Key Points: 
  • This Phase 1-2a study (“AvenActive”) is a double-blind, placebo-controlled, randomized, adaptive, first-in-human study designed to assess safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of avenanthramide.
  • Following the Phase 1 portion, pending successful results, the AvenActive protocol also includes a Phase 2a portion for patients presenting evidence of mild to moderate inflammation.
  • Pending successful results in the Phase 1 and potential Phase 2a study, we believe we will be well-positioned for out-licensing opportunities for later stage development and commercialization.
  • With significant market potential and patient benefit, we believe avenanthramides is poised to be the biggest product for Ceapro,” concluded Gilles Gagnon, M.Sc., MBA, President and CEO of Ceapro.

SOHM, Inc. Expands Its Advisory Board, Appointing Dr. Krishna Bhat, M.D, Ph.D., FACC, as Chief Medical Advisor

Retrieved on: 
Thursday, August 24, 2023

Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor.

Key Points: 
  • Ph.D., FACC., an experienced bioscientist and cardiologist, to serve on the company’s Advisory Board as a Chief Medical Advisor.
  • Baron Night, SOHM president and CEO, said Dr. Bhat has a cardiology practice of over 35 years in the field of Clinical and Interventional Cardiology.
  • Dr. Bhat also received the Miles Canada Fellowship Award and J. Louis Levesque Fellowship Award from Montreal Heart Institute, Montreal, Canada.
  • Dr. Bhat is a renowned Clinical and Interventional Cardiologist who has authored over 16 medical scientific publications.

Dr. Doria A. Scortichini MD, FACC Joins Auburn Heart Institute

Retrieved on: 
Wednesday, July 19, 2023

AUBURN, N.Y., July 19, 2023 /PRNewswire/ -- Dr. Doria Scortichini, MD FACC joins the growing Auburn Heart Institute that is affiliated with Auburn Community Hospital.  Dr. Scortichini is a cardiology specialist in Geneva, New York and has over 40 years of experience in cardiovascular diseases.  Dr. Scortichini graduated from Albany Medical College of Union University and completed her residency and cardiology fellowship at Bronx Municipal Hospital and Albert Einstein College of Medicine Hospital followed by a fellowship in interventional cardiology at the Montreal Heart Institute. Dr. Scortichini is board certified in Internal Medicine and Cardiovascular Diseases.

Key Points: 
  • AUBURN, N.Y., July 19, 2023 /PRNewswire/ -- Dr. Doria Scortichini, MD FACC joins the growing Auburn Heart Institute that is affiliated with Auburn Community Hospital.
  • "We are thrilled to have someone of Dr. Scortichini' s experience join the Auburn Heart Institute and Auburn Community Hospital.
  • "I am excited to join the team at the Auburn Heart Institute, and to be part of Auburn Hospital and this community.
  • Patients can begin scheduling appointments immediately to be seen by Dr. Scortichini at the Auburn Heart Institute 3rd Floor Auburn Community Hospital  - Please call:  315-567-0540 for appointments.

The Montreal Heart Institute Welcomes FDA Approval of Colchicine for the Treatment of Cardiovascular Diseases

Retrieved on: 
Friday, June 23, 2023

MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) welcomes the approval by the United States Food and Drug Administration (FDA) of colchicine for cardiovascular prevention.

Key Points: 
  • MONTREAL, June 23, 2023 (GLOBE NEWSWIRE) -- The Montreal Heart Institute (MHI) welcomes the approval by the United States Food and Drug Administration (FDA) of colchicine for cardiovascular prevention.
  • Two large cardiovascular clinical studies have been conducted with colchicine: COLCOT , conducted by Dr. Jean-Claude Tardif, Director of Research at the Montreal Heart Institute, and LoDoCo-2 , led by Dr. Stefan M. Nidorf from Australia.
  • "We have known for a long time that inflammation contributes to atherosclerosis and increases cardiovascular risk.
  • The results of this study demonstrated that colchicine reduced the risk of cardiovascular events by 31% when added to standard prevention treatments in these patients.

Ceapro Inc. Reports Financial Results for First Quarter 2023 and Provides Corporate Update

Retrieved on: 
Thursday, May 25, 2023

EDMONTON, Alberta, May 25, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO; OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced financial results and operational highlights for the first quarter ended March 31, 2023.

Key Points: 
  • “Our team significantly advanced toward several key milestones related to new product development as well as strategic corporate initiatives.
  • Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
  • Announced positive results from animal studies conducted by Angiogenesis Foundation on a wound healing model.
  • Financial Highlights for the First Quarter Ended March 31, 2023
    Total sales of $3,500,000 for the first quarter of 2023 compared to $6,172,000 for the comparative period in 2022.

Ceapro Inc. Reports Record 2022 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, April 12, 2023

EDMONTON, Alberta, April 12, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO, OTCQX: CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced operational highlights and financial results for the fourth quarter and full year ended December 31, 2022.

Key Points: 
  • “We are very proud of the achievements made in 2022 across all fronts during a year marked by such uncertainties, and economic and operational challenges.
  • Announced highly positive results for bioavailability studies using alginate and yeast beta glucan (YBG) as carriers for coenzyme Q10 (CoQ10).
  • Financial Highlights for the Fourth Quarter and Full Year 2022 Ended December 31, 2022
    Total sales of $3,322,000 for the fourth quarter of 2022 and $18,840,000 for the full year of 2022 compared to $3,562,000 and $17,195,000 for the comparative periods in 2021.
  • Comparative numbers shown for the year 2021 result from a restatement of the financial statements for the year 2021.

Noze Receives $1 Million Grant from Major Global Foundation to Build the World's First Breathalyzer to Detect Infectious Diseases

Retrieved on: 
Tuesday, March 14, 2023

MONTREAL, March 14, 2023 /PRNewswire/ -- Noze (formerly Stratuscent), a Canadian AI startup that has developed the world's leading technology to digitize the sense of smell, today announced a grant of $1 million from the Bill & Melinda Gates Foundation to build a breathalyzer, powered by its platform, to detect breath biomarkers (VOCs). This will enable rapid screening and diagnostics of infectious diseases such as Malaria and Tuberculosis, that impact millions of people, particularly in developing countries.

Key Points: 
  • This will enable rapid screening and diagnostics of infectious diseases such as Malaria and Tuberculosis, that impact millions of people, particularly in developing countries.
  • Healthcare screenings and diagnostics are often time consuming, invasive, costly and not readily accessible to all population groups.
  • To remedy this situation, Noze and the foundation are turning to a groundbreaking, yet largely overlooked source of health information: smell.
  • Development of the diagnostic breathalyzer is targeted for completion by the end of 2023, which will be followed by a clinical validation phase.

Ceapro Inc. Receives Approval from Health Canada to Commence Phase 1/2a Human Clinical Trial Assessing Avenanthramide Tablets

Retrieved on: 
Thursday, December 22, 2022

EDMONTON, Alberta, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Ceapro Inc. (TSX-V: CZO) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, today announced it has received approval from Health Canada to initiate its Phase 1/2a study evaluating the safety, tolerability, bioavailabilty and efficacy of its pharmaceutical grade tablet of avenanthramide as a potential anti-inflammatory product.

Key Points: 
  • The study titled “A Double-Blind, Placebo-Controlled, Randomized, Adaptive, First-in-Human Study to Assess Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral doses of Avenanthramide” as part of the long-term agreement between Ceapro and the prestigious Montreal Heart Institute.
  • This Phase 1/2a trial is a double-blind, placebo-controlled, randomized, adaptive, single- and multiple-dose escalating study in sequential cohorts of healthy subjects, and subjects with low-grade inflammation.
  • Up to 96 subjects may be included in the study and dosages will escalate from 30 mg to 960 mg according to response.
  • Recruitment is anticipated to commence early in 2023.